MoonLake Immunotherapeutics (MLTX)
NEUTRALFondamental
34
Prix
$15.89
Capitalisation boursière
$1.31B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
0
Exercice clos le 31/12/2025
Résultat net
$-227M
Exercice clos le 31/12/2025
Flux de trésorerie libre
$-196M
Capitaux propres totaux
$304M
Passif total
$120M
Ratio de liquidité général
12.56
Couverture des intérêts
26.58
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$28.54
Prix actuel
$15.89
Marge de sécurité
+44.3%
Fourchette de juste valeur
$27.11 - $29.97
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-74.7%
Ratio P/B
3.05
P/FCF
-
Marge brute
-
ROIC
-40.1%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-40.1%
WACC
10.0%
ROIC − WACC
-50.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (7)
- Price CAGR 5.59%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 77% Buy
- Share Dilution 2.3%
Échoué (9)
- EPS shows upward trend
- ROIC -40.1%
- P/B Ratio 3.05
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -85.6%
- Earnings Surprise avg -9.9%
- Piotroski F-Score 1/9
Indisponible (11)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 48 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 37 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | - |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | - |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | - |
| Joana Cortez | Associate Vice-President of Legal & Compliance | - |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | - |
| Luciana Marques | Associate Vice-President of HR, People and Culture | - |
| Ms. Nuala Brennan | Chief Clinical Development Officer | - |
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for MLTX, sourced from Markets Gazette.
- 3/30/2026POSITIVEMoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.
via Markets Gazette